Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
3Customers
2Debt Items
6Related Chains
Source-Backed Evidence Depth
AN2 Therapeutics, Inc. (ANTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
2Distinct source URLs
8High confidence
0.804Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
AN2 Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
JEFFERIES-LLC
JEFFERIES-LLC
92%
the Company may issue and sell from time to time, at its option, up to an aggregate of $80 million of shares of the Company’s common stock, par value $0.00001 per share, through Jefferies, acting as …
ANACOR
ANACOR
90%
Our license agreement with Anacor requires us to satisfy diligence requirements, including using commercially reasonable efforts to develop and commercialize products.
COWEN-AND-COMPANY-LLC
COWEN-AND-COMPANY-LLC
90%
the Company terminated the Sales Agreement (the “TD Cowen Sales Agreement”), dated April 6, 2023, that the Company previously entered into with Cowen and Company, LLC, which was assigned to TD Securi…
TD-SECURITIES-USA-LLC
TD-SECURITIES-USA-LLC
90%
the Company terminated the Sales Agreement (the “TD Cowen Sales Agreement”), dated April 6, 2023, that the Company previously entered into with Cowen and Company, LLC, which was assigned to TD Securi…
Reciprocal relationship from ATEX graph: Reciprocal relationship from ANTX graph: Reciprocal relationship from ATEX graph: Reciprocal relationship from ANTX graph: Reciprocal relationship from ATEX g…
Reciprocal relationship from KZIA graph: Reciprocal relationship from ANTX graph: Reciprocal relationship from KZIA graph: pate will be required to complete clinical development of a product candidat…
AN2 Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
BRII-BIOSCIENCES-LIMITED
BRII-BIOSCIENCES-LIMITED
85%
. As a result, the Company did no t record any research and development expense—related party in the condensed statements of operations for the three months ended March 31, 2026 and 2025. 17 Brii Bio…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
ess for our product candidates may be affected by a variety of risks and uncertainties associated with drug development, including those set forth in the section of this Form 10-Q titled “Risk Factor…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
S. Department of Veterans Affairs. If we become subject to these reporting requirements, we will be liable for errors associated with our submission of pricing data, for failure to report pricing dat…
AN2 Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ANTX-DEBT-7775
Warrants outstanding: 1e-05
90%
xbrl warrant detail from xbrl 2025-06-30.
ANTX-DEBT-7776
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
AN2 Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for AN2 Therapeutics, Inc..
AN2 Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
ANTX-OWNER-VIVO-CAPITAL-LLC
Vivo Capital, LLC
90%
13F overlay lists Vivo Capital, LLC as top holder; 52 tracked holders.
AN2 Therapeutics, Inc. Extended Supply Chain Network
